 During Q2, Seres Therapeutics NASDAQ: MCRB reported sales totaled 6.04 million. Despite a 4.33 in earnings, the company posted a loss of 20.55 million. In Q1, Seres Therapeutics brought in 8.19 million in sales but lost 19.69 million in earnings.Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a companys ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Seres Therapeutics posted an ROCE of 0.31.Keep in mind, while ROCE is a good measure of a companys recent performance, it is not a highly reliable predictor of a companys earnings or sales in the near future.View more earnings on MCRBROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Seres Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.In Seres Therapeuticss case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.Q2 Earnings Insight Seres Therapeutics reported Q2 earnings per share at -0.28share, which did not meet analyst predictions of -0.26share.See more from Benzinga Stocks That Hit 52-Week Highs On Monday Morning Market Stats in 5 Minutes Recap: Seres Therapeutics Q2 EarningsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 